Spectral MD Holdings, Ltd
("Spectral MD" or the "Company")
Block Admission
LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI and optical technology for faster and more accurate treatment decisions in wound care, announces that a block listing application ("Block Listing") has been made to the London Stock Exchange for up to 2.0 million shares of common stock of US $0.001 ("Common Stock") in the Company ("Shares") to be admitted to trading on AIM.
These Shares will be issued and allotted from time to time pursuant to the exercise of employee options which have been issued pursuant to the Company's 2018 Long-Term Incentive Plan and have varying exercise prices from US $0.02 to US $0.53 per share.
The Block Listing has been filed to enable holders of the Company's options to continue to voluntarily exercise them without the need for the issue of a separate RNS and admissions filing each time this occurs. The Company will notify on a monthly basis when there are changes to the issued share capital of the Company, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company. The Company will also make announcements every six months regarding the utilisation of the block admission in line with its obligations under AIM Rule 29. It is expected that the Block Listing will become effective on or around November 8, 2022.
If and when issued, the Shares will rank pari passu in all respects with the existing Common Stock of the Company.
As at the date of this announcement, the total number of Common Stock in the Company is 136,249,564, with one voting right per Share. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company under the Company's Certificate of Incorporation. No Common Stock is held in treasury.
For further information please contact:
| Spectral MD Holdings, Ltd. | investors.spectralmd.com | |
| Wensheng Fan, Chief Executive Officer | via Walbrook PR | |
| Nils Windler, Chief Financial Officer |
| |
|
|
| |
| SP Angel Corporate Finance LLP (NOMAD and Joint Broker) | Tel: +44 (0)20 3470 0470 | |
| Stuart Gledhill/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Sales & Broking)
Stifel Nicolaus Europe Limited (Joint Broker) Charles Hoare / Ben Maddison / Nick Harland / Will Palmer-Brown |
Tel: +44 (0)20 7710 7600 | |
|
|
| |
| Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com | |
| Paul McManus / Louis Ashe-Jepson Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393 +44 (0)7407 804 654 | |
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.
www.spectralmd.com
info@spectralmd.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.